Sidley represented Clear Labs, a provider of fully automated, next-generation sequencing platforms for turnkey diagnostics, in its US$30 million Series D financing. The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc.
The Sidley team was led by Carlton Fleming (Emerging Companies and Venture Capital) and included BinQuan Zhuang, Ph.D. (M&A), Daniel Wei (Emerging Companies and Venture Capital), and Benjamin Farkas (Securities Enforcement and Regulatory).
